News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Hatem Soliman, MD

Articles by Hatem Soliman, MD

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

ByKatheryn Moreira,Kathryn Hudson,Wambui Gathirua-Mwangi,Zhanglin Lin Cui,Madeline Richey,Brenda Grimes,Jingru Wang,Astra Liepa,Erich Brechtelsbauer,Raisa Volodarsky,Hatem Soliman, MD

May 24th 2025

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD

April 28th 2023

Propelling Immunotherapy Combinations Into the Clinic

ByNishan Tchekmedyian, MD,Jhanelle E. Gray, MD,Benjamin C. Creelan, MD,Alberto A. Chiappori, MD,Amer A. Beg, PhD,Hatem Soliman, MD,Bradford A. Perez, MD,Scott J. Antonia, MD, PhD

December 16th 2015

This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.

Latest Updated Articles

Propelling Immunotherapy Combinations Into the Clinic
Published: December 16th 2015 | Updated:

Trending on CancerNetwork

Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention

2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?

Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma

Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC

Outlining Advances in AI For Breast Cancer Screening/Radiomics